Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | TSPO | P30536 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886234 | 1.00 | LMNA (0.52) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL22208756 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL31697111 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL23214513 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL29663846 | 0.85 | LMNA (0.61) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL22208577 | 0.84 | LMNA (0.53) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL31697274 | 0.84 | LMNA (0.53) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL23216376 | 0.83 | LMNA (0.58) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL25085813 | 0.80 | LMNA (0.45) | LMNASMN1; SMN2TSHRMEN1KMT2A | |
| SCHEMBL22372573 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-01-26 | — | — | US | disclosed |
| EP-4041407-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021071802-A1 | ARYL HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-2691393-B1 | NOVEL BICYCLIC PYRIDINONES | PFIZER (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9067934-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8697673-B2 | Bicyclic pyridinones | PFIZER INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140045790-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2691393-A1 | NOVEL BICYCLIC PYRIDINONES | Pfizer Inc (US) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012131539-A1 | NOVEL BICYCLIC PYRIDINONES | PFIZER INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | PFIZER INC. | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045790-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2C19, CYP2D6 | LMNA 1689/4885SMN1; SMN2 1736/4885TSHR 2424/4885 |
| US-20230026611-A1 | ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNA3, KCNH2, KCNJ2 | LMNA 2534/4885SMN1; SMN2 2503/4885TSHR 1706/4885 |
| US-20120252758-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2C19, CYP2D6 | LMNA 1689/4885SMN1; SMN2 1736/4885TSHR 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.